endometrial clear cell adenocarcinoma (Cancer)
Information
- Disease name
- endometrial clear cell adenocarcinoma
- Disease ID
- DOID:5299
- Description
- "An endometrial adenocarcinoma that is characterized by the presence of cells with clear cytoplasm." [url:https\://www.ncbi.nlm.nih.gov/pubmed/24817975]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03914612 | Active, not recruiting | Phase 3 | Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer | July 16, 2019 | May 10, 2024 |
| NCT00942357 | Active, not recruiting | Phase 3 | Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer | June 29, 2009 | July 28, 2024 |
| NCT01737619 | Active, not recruiting | N/A | PET/CT and Lymph Node Mapping in Finding Lymph Node Metastasis in Patients With High-Risk Endometrial Cancer | April 3, 2013 | April 30, 2025 |
| NCT01935934 | Active, not recruiting | Phase 2 | Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer | April 29, 2013 | March 26, 2025 |
| NCT00977574 | Active, not recruiting | Phase 2 | Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | September 14, 2009 | March 6, 2025 |
| NCT02020707 | Active, not recruiting | Phase 1 | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers | February 24, 2014 | June 30, 2025 |
| NCT02874430 | Active, not recruiting | Phase 2 | Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer | June 8, 2016 | June 2023 |
| NCT02142803 | Active, not recruiting | Phase 1 | TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors | May 20, 2014 | October 1, 2024 |
| NCT01132820 | Completed | Phase 2 | Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer | June 2010 | January 2016 |
| NCT01210222 | Completed | Phase 2 | Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer | June 6, 2011 | July 16, 2016 |
| NCT01225887 | Completed | Phase 2 | Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer | October 2011 | January 2016 |
| NCT01307631 | Completed | Phase 2 | Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer | March 2011 | September 18, 2015 |
| NCT01440998 | Completed | Phase 1 | Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer | September 20, 2011 | December 31, 2015 |
| NCT01642082 | Completed | Phase 2 | Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer | September 2012 | January 2016 |
| NCT01935973 | Completed | Phase 1 | Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer | September 30, 2013 | September 8, 2015 |
| NCT00005830 | Completed | Phase 1 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer | July 2000 | |
| NCT00005840 | Completed | Phase 1 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer | July 2000 | |
| NCT00006011 | Completed | Phase 3 | Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer | July 2000 | |
| NCT00575952 | Completed | Phase 1 | Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer | January 17, 2008 | July 16, 2016 |
| NCT00820898 | Completed | Phase 2 | Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer | February 2009 | |
| NCT00888173 | Completed | Phase 2 | Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer | July 6, 2009 | July 16, 2016 |
| NCT01005329 | Completed | Phase 2 | Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer | November 6, 2009 | September 22, 2013 |
| NCT01011933 | Completed | Phase 2 | Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer | September 2009 | January 2016 |
| NCT02501954 | Completed | Phase 3 | Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol | March 2015 | November 2023 |
| NCT05950464 | Recruiting | Phase 1 | Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer | December 18, 2023 | April 30, 2026 |
| NCT05001282 | Recruiting | Phase 1/Phase 2 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) | September 13, 2021 | June 15, 2025 |
| NCT05049538 | Recruiting | Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in High-Risk Endometrial Cancers | June 18, 2019 | June 30, 2024 | |
| NCT05112601 | Recruiting | Phase 2 | Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma | June 2, 2022 | April 30, 2026 |
| NCT05498597 | Recruiting | Phase 1 | AMT-151 in Patients With Selected Advanced Solid Tumours | January 25, 2023 | October 30, 2024 |
| NCT03422198 | Recruiting | Phase 3 | Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer | January 30, 2018 | October 31, 2029 |
| NCT02059265 | Terminated | Phase 2 | Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer | February 14, 2014 | June 26, 2023 |
| NCT02065687 | Unknown status | Phase 2/Phase 3 | Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer | March 17, 2014 | September 13, 2023 |
| NCT00807768 | Unknown status | Phase 3 | Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer | March 23, 2009 | |
| NCT03836157 | Withdrawn | Phase 2 | Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer | May 31, 2019 | May 2022 |
- Disase is a (Disease Ontology)
- DOID:2870
- Cross Reference ID (Disease Ontology)
- NCI:C8028
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0279765
- Exact Synonym (Disease Ontology)
- Clear cell carcinoma of Endometrium